Healthy subjects
Conditions
Interventions
"
Catechin"
powder (Sanphenon EGCg-OP: manufactured and sold as a supplement by Taiyo Kagaku) is used. The EGCg intake is set to 300 mg / day and the intake period is 4 weeks (28 days).
Sponsors
Kyoto Prefectural University of Medicine
Laboratory of Animal Science, Setsunan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. An adult (regardless of gender) who can obtain a written consent to participate in the research from the person himself / herself. 2. Those who are between the ages of 50 and 70 at the time of obtaining consent (regardless of gender) 3. Those who can comply with the following lifestyle habits during the test period from one week before the start of the test Do not consume green tea. Do not consume many foods with high polyphenol content such as chocolate. Do not take antibiotics. Do not use mouthwash or mouthwash. Refrain from taking probiotics (mainly yogurt). Do not take natto. Do not smoke Do not take prebiotics (dietary fiber and oligosaccharide supplements).
Exclusion criteria
Exclusion criteria: 1. Those who are treating diseases that affect the research results (dental and oral diseases, digestive diseases, etc.) 2. Those who have an extremely irregular diet 3. Those who drink a lot of green tea and alcohol on a daily basis 4. Those who habitually engage in strenuous exercise such as marathons 5. Currently, under the guidance of a doctor, those who are or will be doing exercise therapy / diet therapy 6. Serious heart disease [heart failure, myocardial infarction, myocarditis, etc.], liver disease [liver failure symptoms (fulminant hepatitis), liver cirrhosis, liver tumor], renal disease [nephrotic syndrome, renal failure (acute and chronic), urinary poisoning Disease, hydronephrotic syndrome], neurological disease, psychiatric disease, malignant tumor disease, etc., and those who have general condition problems 7. Those who have participated in other clinical trials within one month before obtaining consent or who plan to participate in other clinical trials during the trial period. 8. In addition, those who are judged by the investigator to be inappropriate for the study (the risk to the study subject may increase or sufficient data may not be obtained).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To analyze the change of oral bacteria and fecal bacteria before and after catechin intake by 16S rRNA metagenomic analysis by Illumina Miseq. | — |
Secondary
| Measure | Time frame |
|---|---|
| Bile acids and short-chain fatty acids in the stool before and after ingestion, and urinary metabolites are measured before and after catechin intake as metabolites of intestinal bacteria. | — |
Countries
Japan
Contacts
Public ContactYuji Naito
Kyoto Prefectural University of Medicine Molecular Gastroenterology and Hepatology
Outcome results
None listed